Survodutide (GCG/GLP-1) — MASH and obesity trial results

One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

A narrower follow-up, since the general answer is now clear:

Whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is?

Dr.RaviCardio said:

With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…

Adding the part of the answer the thread has not reached. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.

Closing the loop on my own question.

Update — I was wrong in the opening post, specifically about the direction. Correcting it here rather than editing it away.

BariatricNurseD said:

It is worth asking what the claim would look like if it were false.

No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

I would rather be corrected than agreed with, if it comes to it.